Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tedizolid Phosphate in Hospitalized Children 2 to <12 Years
NCT02750761Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tedizolid in Gram-positive bacterial infection, sponsored by Merck & Co. Primary endpoints: Maximum Observed Drug Concentration in Plasma of Tedizolid Phosphate at 48 hours, Time to Reach Peak Plasma Concentration of Tedizolid Phosphate at 48 hours and 8 more. Started May 2016; status: completed.
02
Drugs
tedizolid
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT02750761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750761.